News
2d
TipRanks on MSNMerck Stock (MRK) Bulls Cheer $10Bn Verona Pharma GambleMerck & Co. ($MRK) is betting on acquisitions to offset the looming revenue loss from the upcoming patent expiration of ...
Verona Pharma brings to Merck the inhaled drug Ohtuvayre, which is FDA approved as a treatment for chronic obstructive ...
Verona brings with it Ohtuvayre, an inhaled treatment for chronic obstructive pulmonary disease, often known as smoker's lung. The drug was approved earlier this year and has generated $42.3 million ...
The deal gives Merck access to Verona Pharma’s new chronic obstructive pulmonary disease medication Ohtuvayre.
M erck said Wednesday it would pay $10 billion to buy the biotech Verona Pharma, which sells a new lung-disease drug that ...
Merck’s recent acquisition announcement sends a strong signal regarding its urgency to tackle the impending Keytruda patent ...
Merck has pulled off another acquisition which fits in its “sweet spot,” as described by CEO Rob Davis, paying $10 billion ...
Verona Pharma’s flagship drug last year became the first new maintenance treatment for chronic obstructive pulmonary disease ...
Merck announces plans of buying Verona for a huge premium. VRNA deal could shield Merck from two major headwinds.
Merck said it will buy Verona Pharma for $10 billion to bolster its lung-disease business and help replace the expected loss ...
Merck & Co. is acquiring Verona Pharma PLC in a $10 billion deal that will expand the pharmaceutical giant’s portfolio of ...
The move bolsters Merck's lineup as it braces for the 2028 loss of patent exclusivity for blockbuster cancer drug Keytruda.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results